Table 3.

Modified Sharp Scores at baseline, week 48, and week 102, as well as changes in modified Sharp scores from baseline to week 102, by treatment group^*

	Assessment						Change in modified Sharp Score
Group (N)	Baseline		48 weeks		102 weeks
Total	Median (range)	Mean ± SD	Median (range)	Mean ± SD	Median (range)	Mean ± SD	Median (range)	Mean ± SD
Immediate Combination Therapy (n = 330)	2 (0-175.5)	7 ± 14.9	3 (0-174.5)	7.9 ± 15.9	3.0 (0-175.5)	7.5 ± 15.7	0 (−13-78.5)	1.1 6.4
Step Up to Combination Therapy (n = 236)	2 (0-117.5)	6.2 ± 13.4	2.5 (0-115.5)	7.3 ± 14.6	2.8 (0-52)	6.2 ± 8.7	0 (−4-32)	1.2 ± 4.1
MTX Monotherapy (n = 84)	1.5 (0-19)	2.9 ± 3.5	1.5 (0-19.5)	2.9 ± 3.6	1.3 (0-14)	2.6 ± 2.9	0 (−1.5-5)	0.2 ± 1.1

^*P values across treatment groups were significant at week 48 (P = 0.0321) and week 102 (P = 0.0074), as was the change in modified Sharp score at week 102 (P = 0.0467). MTX = methotrexate.